Dr Ronald Michael Saldino, MD in Hot Springs Village, AR - Radiology

Dr Ronald Michael Saldino, MD is a Radiology - Diagnostic Radiology physician based in Hot Springs Village, Arkansas. Dr Ronald Michael Saldino is licensed to practice in California (license number GFE 15448) and his current practice location is 10 Guindola Ln, Hot Springs Village, Arkansas. He can be reached at his office (for appointments etc.) via phone at (501) 922-1475.

NPI number for Dr Ronald Michael Saldino is 1629268578 and his current mailing address is 10 Guindola Ln, Hot Springs Village, Arkansas. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1629268578.

Contact Information

	Dr Ronald Michael Saldino, MD
	10 Guindola Ln, Hot Springs Village, AR 71909-7137
	(501) 922-1475
	Not Available

Physician's Profile

Full Name	Dr Ronald Michael Saldino
Gender	Male
Speciality	Radiology - Diagnostic Radiology
Location	10 Guindola Ln, Hot Springs Village, Arkansas
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1629268578
Provider Enumeration Date: 07/26/2007
Last Update Date: 07/26/2007

Medical Identifiers

Medical identifiers for Dr Ronald Michael Saldino such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1629268578	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
2085R0202X	Radiology - Diagnostic Radiology	GFE 15448 (California)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Ronald Michael Saldino is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Ronald Michael Saldino, MD 10 Guindola Ln, Hot Springs Village, AR 71909-7137 Ph: (501) 922-1475	Dr Ronald Michael Saldino, MD 10 Guindola Ln, Hot Springs Village, AR 71909-7137 Ph: (501) 922-1475

News Archive

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

NovaBay Pharmaceuticals, Inc. today announced that its lead product candidate was safe and efficacious against the highly contagious skin infection impetigo in a Phase 2a proof-of-concept clinical trial. This dose-ranging study showed that the drug cleared impetigo infections, including those in the trial caused by a drug-resistant strain of bacteria called methicillin-resistant Staphylococcus aureus or MRSA. Impetigo afflicts approximately 1 million people, primarily infants and children, in the United States annually.

As state legislatures gear up, federal health overhaul is on their agenda

The New York Times Prescriptions Blog: "The question of equality, or inequality, among states is a major reason President Obama's overhaul of the health care system, and the legislation in Congress to make it happen, seemed to reach the brink of collapse last week." The issue also reflects "one of the biggest challenges" the President and Congressional leaders face in their efforts to overhaul the health care system. The key question: "how to devise a national solution for a problem that varies sharply from state to state."

Obesity predisposition linked to brain's reward system

The tendency toward obesity is directly related to the brain system that is involved in food reward and addictive behaviors, according to a new study. Researchers at Tufts University School of Medicine (TUSM) and colleagues have demonstrated a link between a predisposition to obesity and defective dopamine signaling in the mesolimbic system in rats.

Old and poor people are less likely to have knee replacement surgery

Old and poor people are less likely to have knee replacement surgery, although their need is often greater than that of younger, more affluent people, reveals a large scale study in the Annals of the Rheumatic Diseases.

Combined gene therapy eliminates glioblastoma multiforme in lab studies

Despite aggressive treatment, glioblastoma multiforme (GBM) - the most common and deadly of brain cancers - usually claims the lives of its victims within six to 12 months of diagnosis. Because GBM is so aggressive, the disease has been the target of a number of laboratory and clinical studies investigating the effectiveness of gene therapy to deliver novel therapies to the brain.

Dr Ronald Michael Saldino, MD - Radiology in Hot Springs Village, AR